<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069081</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2010-01</org_study_id>
    <nct_id>NCT01069081</nct_id>
  </id_info>
  <brief_title>Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Docetaxel and Cisplatin Chemotherapy Versus Docetaxel and Cisplatin Chemotherapy Combined With High Dose Proton Pump Inhibitor in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Superiore di Sanità</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the efficacy and tolerability of high dose
      proton pump inhibitor combined with chemotherapy in metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High dose proton pump inhibitor (PPI) has been proved beneficial and it improved efficacy
      when combined with chemotherapy in preclinical and clinical trials.This study was designed to
      explore whether adding a proton pump inhibitor into docetaxel and cisplatin chemotherapy
      improves efficacy and does not affect tolerability in metastatic breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure,Objective response,Overall survival,Safety</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastasis, Neoplasm</condition>
  <arm_group>
    <arm_group_label>arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel and cisplatin chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm C</intervention_name>
    <description>Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.</description>
    <arm_group_label>arm C</arm_group_label>
    <other_name>docetaxel</other_name>
    <other_name>cisplatin</other_name>
    <other_name>esomeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm B</intervention_name>
    <description>Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.</description>
    <arm_group_label>arm B</arm_group_label>
    <other_name>Docetaxel</other_name>
    <other_name>cisplatin</other_name>
    <other_name>esomeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A</intervention_name>
    <description>Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.</description>
    <arm_group_label>arm A</arm_group_label>
    <other_name>Docetaxel</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Female, ≥ 18 years.

          -  Histologically confirmed invasive breast cancer.

          -  Metastatic breast cancer.

          -  Karnofsky Performance Status ≥60.

          -  Life expectancy of more than 3 months.

          -  Subject must have adequate organ function.

          -  Normal laboratory values: hemoglobin &gt; 80g/dl, neutrophils &gt; 2.0×10^9/L, platelets &gt;
             80×10^9/L, serum creatinine &lt; upper limit of normal (ULN), serum bilirubin &lt; ULN, ALT
             and AST &lt; 2.5×ULN, AKP &lt; 5×ULN.

          -  Negative serum pregnancy test for women with childbearing potential.

          -  Good conditions for infusion and willing to have phlebotomy throughout whole study.

          -  Have ceased anti-tumor treatments including endocrinotherapy and bio-targeted therapy
             for more than 28 days.

          -  Have at least one target lesion according to the Response Evaluation Criteria in Solid
             Tumors (RECIST) criteria.

          -  No prior use of docetaxel or has used docetaxel in adjuvant/neo-adjuvant chemotherapy
             and has a relapse free survival of at least 12 months.

        Exclusion Criteria:

          -  Pregnant or lactating females.

          -  History of other malignancy. However, subjects who have been disease-free for 5 years,
             or subjects with a history of completely resected non-melanoma skin cancer or
             successfully treated in situ carcinoma are eligible.

          -  Concurrent disease or condition that would make the subject inappropriate for study
             participation, or any serious medical disorder that would interfere with the subject's
             safety.

          -  Active or uncontrolled infection.

          -  Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart
             failure.

          -  Concomitant with brain metastases.

          -  Have received chemotherapy after metastasis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XiChun Hu, MD,Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Chiesi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Superiore di Sanità</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Fais, MD PHD</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Superiore di Sanità</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Metastasis Breast Cancer</keyword>
  <keyword>Proton Pump Inhibitor</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Phase II study</keyword>
  <keyword>TTP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

